GRAIL wins FDA panel backing as Galleri trial results strengthen its case
Advisory panel support is a key step toward U.S. approval for the multi-cancer blood test, a product whose commercial future has been closely watched since GRAIL's spinoff.
Read at Simply Wall St →Full coverage · 8 outlets
- Simply Wall St · lead
- Yahoo FinanceWhat GRAIL (GRAL)'s Canada Test Rollout Means For Shareholders
- GRAILFDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test
- NPRFDA advisory panel recommends a first: multi-cancer blood test
- Medical DailyCancer Blood Test Galleri Nears FDA Decision as Screening Researcher Warns Its Main Trial Missed Its Goal
- Star TribuneCancer blood test advances toward FDA approval after Mayo research
- YahooGrail multicancer detection test wins FDA advisers’ backing
- YahooGRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued?